JP Morgan Chase’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.43K | Sell |
1,915
-24,809
| -93% | -$39.4K | ﹤0.01% | 7190 |
|
|
2026
Q1 | $41.4K | Buy |
26,724
+747
| +3% | +$1.53K | ﹤0.01% | 6274 |
|
|
2025
Q4 | $73K | Buy |
25,977
+1,006
| +4% | +$2.34K | ﹤0.01% | 6064 |
|
|
2025
Q3 | $51.4K | Sell |
24,971
-5,862
| -19% | -$16.2K | ﹤0.01% | 6219 |
|
|
2025
Q2 | $97.1K | Buy |
30,833
+3,065
| +11% | +$9.35K | ﹤0.01% | 5623 |
|
|
2025
Q1 | $87.2K | Buy |
27,768
+8,319
| +43% | +$32.9K | ﹤0.01% | 5640 |
|
|
2024
Q4 | $84.4K | Buy |
19,449
+2,043
| +12% | +$6.38K | ﹤0.01% | 5813 |
|
|
2024
Q3 | $46.5K | Buy |
17,406
+685
| +4% | +$1.62K | ﹤0.01% | 6015 |
|
|
2024
Q2 | $37.1K | Buy |
16,721
+16,695
| +64,212% | +$62.9K | ﹤0.01% | 5969 |
|
|
2024
Q1 | $139 | Hold |
26
| – | – | ﹤0.01% | 6859 |
|
|
2023
Q4 | $38 | Sell |
26
-17,528
| -100% | -$21.2K | ﹤0.01% | 7240 |
|
|
2023
Q3 | $24.4K | Buy |
17,554
+17,528
| +67,415% | +$29.6K | ﹤0.01% | 6019 |
|
|
2023
Q2 | $38 | Hold |
26
| – | – | ﹤0.01% | 6759 |
|
|
2023
Q1 | $0 | Hold |
26
| – | – | ﹤0.01% | 6767 |
|
|
2022
Q4 | $0 | Hold |
26
| – | – | ﹤0.01% | 6604 |
|
|
2022
Q3 | $0 | Hold |
26
| – | – | ﹤0.01% | 6503 |
|
|
2022
Q2 | $0 | Sell |
26
-17,861
| -100% | -$29.9K | ﹤0.01% | 6516 |
|
|
2022
Q1 | $44K | Sell |
17,887
-1,846
| -9% | -$6.53K | ﹤0.01% | 5844 |
|
|
2021
Q4 | $118K | Buy |
19,733
+277
| +1% | +$1.65K | ﹤0.01% | 5603 |
|
|
2021
Q3 | $130K | Buy |
19,456
+1,378
| +8% | +$8.66K | ﹤0.01% | 5436 |
|
|
2021
Q2 | $121K | Buy |
18,078
+14,343
| +384% | +$122K | ﹤0.01% | 5476 |
|
|
2021
Q1 | $35K | Buy |
3,735
+1,734
| +87% | +$21.1K | ﹤0.01% | 5615 |
|
|
2020
Q4 | $36K | Buy |
+2,001
| New | +$35.2K | ﹤0.01% | 5217 |
|
|
2020
Q2 | – | Sell |
-2
| Closed | – | – | 5416 |
|
|
2020
Q1 | $0 | Sell |
2
-844
| -100% | -$1.19K | ﹤0.01% | 5352 |
|
|
2019
Q4 | $1K | Buy |
+846
| New | +$1.21K | ﹤0.01% | 5554 |
|
|
2019
Q3 | – | Sell |
-846
| Closed | -$2K | – | 5748 |
|
|
2019
Q2 | $2K | Hold |
846
| – | – | ﹤0.01% | 5684 |
|
|
2019
Q1 | $3K | Sell |
846
-1
| -0.1% | -$4 | ﹤0.01% | 5653 |
|
|
2018
Q4 | $3K | Buy |
847
+836
| +7,600% | +$3.81K | ﹤0.01% | 5570 |
|
|
2018
Q3 | $0 | Hold |
11
| – | – | ﹤0.01% | 5685 |
|
|
2018
Q2 | $0 | Hold |
11
| – | – | ﹤0.01% | 5556 |
|
|
2018
Q1 | $0 | Hold |
11
| – | – | ﹤0.01% | 5419 |
|
|
2017
Q4 | $0 | Hold |
11
| – | – | ﹤0.01% | 5445 |
|
|
2017
Q3 | $1K | Buy |
+11
| New | +$686 | ﹤0.01% | 4903 |
|
|
2016
Q1 | – | Sell |
-14
| Closed | -$6K | – | 4691 |
|
|
2015
Q4 | $6K | Buy |
+14
| New | +$5.48K | ﹤0.01% | 4298 |
|
Other funds holding CRDF
LCM
P
JP Morgan Chase's CRDF Position: Q2 2026 in Review
JP Morgan Chase reduced its Cardiff Oncology (CRDF) stake by 93% in Q2 2026, selling an estimated $39.4K and leaving 1,915 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #7190.
JP Morgan Chase first reported a position in CRDF in Q4 2015 and has held it in 34 quarters since. The position peaked at $130K in Q3 2021. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- JP Morgan Chase held 1,915 shares of Cardiff Oncology worth $2.43K as of Q2 2026.
- JP Morgan Chase sold 24,809 Cardiff Oncology shares in Q2 2026, an estimated $39.4K.
- Cardiff Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7190 holding.
- JP Morgan Chase first reported a position in Cardiff Oncology in Q4 2015 and has held it in 34 quarters since.
- JP Morgan Chase's Cardiff Oncology position peaked at $130K in Q3 2021.
- 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.